Clot-busting drug safe for stroke patients taking blood thinner

May 10, 2012

Acute ischemic stroke patients taking the blood thinner warfarin can be treated safely with the clot-busting drug tissue plasminogen activator (tPA), according to research presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2012.

"Although it's the only drug approved by the to treat , tPA is underused among patients on home warfarin therapy mainly because of the fear that it will cause bleeding," said Ying Xian, M.D., Ph.D., the study's lead author and a research fellow at Duke Clinical Research Institute, in Durham, N.C.

Xian and colleagues used data from the /American Stroke Association's Get With The Guidelines®-Stroke registry to evaluate tPA safety in warfarin-treated patients who had an ischemic stroke, which occurs when a blood vessel to the brain becomes blocked.

The data was from 23,437 ischemic treated with tPA in 1,203 Get With The Guidelines-Stroke hospitals between April 2009 and June 2011. Almost 8 percent (1,802) of patients were taking warfarin prior to admission.

Patients on warfarin prior to hospitalization for an tended to be older (77 years vs. 71 years), had more illnesses at the time of their strokes and had more severe strokes than patients not on warfarin.

Nevertheless, the risk of severe bleeding from brain hemorrhage was similar among stroke patients who received tPA after stroke, regardless of whether they were on warfarin.

The researchers also didn't find notable differences between warfarin and non-warfarin patients when they compared risks of tPA-related complications or in-hospital death after tPA.

"Our study suggests tPA is not associated with excessive bleeding or death among warfarin patients, when used according to American Heart Association/American Stroke Association guidelines," Xian said. "tPA has been shown to minimize brain damage and disability from stroke and should not be withheld from these patients."

The study is the largest on the safety of tPA in warfarin-treated patients who meet clinical guideline criteria. However, Xian said they didn't measure functional, neurological or long-term results of tPA treatment.

Explore further: Use of clot busters for stroke increased from 2005 to 2009, but still low

Related Stories

Use of clot busters for stroke increased from 2005 to 2009, but still low

June 2, 2011
The use of clot-busting drugs to treat acute ischemic stroke increased from 2005 through 2009 — but is still low, according to research reported in Stroke: Journal of the American Heart Association.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.